How many mg per day of Vesugen, and how long is a cycle?

Neither figure can be sourced, so neither is published here. No controlled trial meeting modern standards has established a Vesugen dose, there is no approved product in the United States to carry a label, and the FDA has never evaluated it — it was never even nominated for the 503A list, so it appears in no category. The milligrams-per-day figures and the ten-day or twenty-day “cycles” you will find quoted confidently elsewhere trace back to vendor product pages and to other dosage calculators repeating one another, not to any study. We can tell you that they have no primary source; we cannot tell you a better number, because there isn't one.

How do I reconstitute a 20 mg Vesugen vial?

The arithmetic is the same as for any vial and carries no dosing claim. 20 mg with 2 mL of bacteriostatic water gives 10 mg/mL, so 1 mg of solution would be 0.1 mL — 10 units on a U-100 syringe. With 1 mL the same vial is 20 mg/mL and that same 1 mg falls to 5 units, which is about as low as a barrel can be read without the misread of a single mark becoming a 20% error. That tells you what is in a given draw. It does not tell you that 1 mg is a dose, and nothing published says it is.

Vesugen Dosage Calculator (KED Tripeptide)

A synthetic tripeptide from the Khavinson “peptide bioregulator” programme. The weakest evidence base of anything on this site.

Written by Kashif Khan, who builds and maintains this site and is not a clinician. Every figure links to its primary source.

Not approved

Not approved; never evaluated by the FDA

Vesugen is on no FDA compounding list — not Category 1, 2 or 3. It was never nominated, so no FDA evaluation has ever taken place.

No approved human dose exists for this compound in any country. The figures below are the doses used in named published studies, reproduced for reference only. Doses given to rats or mice do not convert to a human dose. The FDA has stated that labelling a product “research use only” or “not for human consumption” does not change its legal status when the seller's own marketing shows it is intended for people.

Calculator inputs

Set up your vial

Enter the label, dilution and dose. The result updates as you type.

Syringe volume

Vesugen in the vial

Vials sold online are commonly 10–20 mg

Bacteriostatic water to add

Dose per injection

No approved human dose exists for this compound. The dose shown is only a calculator input, not a recommendation or starting point.

More optionsReverse calculation, schedule and cost

Enter the bacteriostatic water you added and get the volume to draw.

Injections per week

Discard afterdays

Vial priceoptional

Draw to

10units(0.1 mL)

Concentration: 10 mg/mL
Water added: 2 mL
Doses in vial: 20

How the concentration is calculated

This divides the peptide by the water you add. The powder occupies a little volume of its own, which is negligible on a typical vial but not on one with a heavy bulking agent. When a product label states a concentration, use the label’s number.

Key facts

Molecular weight: 390.39 Da
Half-life: Not published. No accessible human pharmacokinetic study reports one, so any specific figure quoted elsewhere has no primary source behind it.
Also sold as: KED, Lys-Glu-Asp

Published doses

None. No study has published a dose for Vesugen that can be responsibly reproduced. That is a finding, not an omission — every dose figure you see for it elsewhere online comes from community convention rather than a source.

How good is the evidence?

The weakest evidence on this entire site: roughly 27 indexed publications, essentially all from investigators affiliated with the originating institute, mostly in-vitro endothelial work plus small Russian-language clinical reports that do not meet modern randomised-trial methodology, with no independent replication of any core claim. No dose from a controlled trial meeting modern standards exists, so none is reproduced here.

What a search of the literature actually returns

It is worth stating what the evidentiary gap here consists of, rather than leaving it as a vague warning. The indexed literature runs to roughly 27 publications. Essentially all of them come from investigators affiliated with the originating institute. The bulk is in-vitro endothelial work, supplemented by small Russian-language clinical reports that do not meet modern randomised-trial methodology. No core claim has been independently replicated.

That is a different situation from a compound that has been tested and found wanting, and different again from one that is simply new. It is a body of work that has never been subjected to the step — independent replication — that turns a result into a finding.

Never nominated, so never evaluated

Vesugen appears on no FDA compounding list — not Category 1, not Category 2, not Category 3. The reason is procedural rather than substantive: the lists are populated by nomination, and nobody nominated it. No FDA evaluation of this compound has ever taken place.

Absence from the lists therefore carries no information about safety in either direction. It is frequently presented as though it did, usually by vendors pointing out that the compound has not been restricted. Nothing has been concluded about it at all, which is the least informative regulatory position a substance can be in.

Common questions

Sources

Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.

RegulatorFDA· 2026-05-14
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
ReferenceNIH / National Center for Biotechnology Information
PubChem compound records (molecular weights and formulae)
ReferenceNIH / National Library of Medicine
PubMed — biomedical literature database
RegulatorFDA
Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act